Shaw KA, Cutler DJ, Okou D, et al. Genetic variants and pathways implicated in a pediatric inflammatory bowel disease cohort. Genes Immun. 2019;20(2):131-142. doi:10.1038/s41435-018-0015-2
van Doormaal PTC, Ticozzi N, Weishaupt JH, et al. The role of de novo mutations in the development of amyotrophic lateral sclerosis. Hum Mutat. 2017;38(11):1534-1541. doi:10.1002/humu.23295
May P, Girard S, Harrer M, et al. Rare coding variants in genes encoding GABA receptors in genetic generalised epilepsies: an exome-based case-control study. Lancet Neurol. 2018;17(8):699-708. doi:10.1016/S1474-4422(18)30215-1
Mahajan A, Wessel J, Willems SM, et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet. 2018;50(4):559-571. doi:10.1038/s41588-018-0084-1
Manier S, Park J, Capelletti M, et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun. 2018;9(1):1691. doi:10.1038/s41467-018-04001-5
Flannick J, Mercader JM, Fuchsberger C, et al. Exome sequencing of 20,791Â cases of type 2 diabetes and 24,440Â controls. Nature. 2019;570(7759):71-76. doi:10.1038/s41586-019-1231-2
Heinzen EL, O’Neill AC, Zhu X, et al. De novo and inherited private variants in MAP1B in periventricular nodular heterotopia. PLoS Genet. 2018;14(5):e1007281. doi:10.1371/journal.pgen.1007281
Ng SY, Yoshida N, Christie AL, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9(1):2024. doi:10.1038/s41467-018-04356-9
Pectasides E, Stachler MD, Derks S, et al. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018;8(1):37-48. doi:10.1158/2159-8290.CD-17-0395
Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018;8(6):714-729. doi:10.1158/2159-8290.CD-17-1256